On September 15, 2022 Athebio AG, an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), reported that it has entered into a collaboration agreement with 3T Biosciences ("3T"), an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach (Press release, AtheBio, SEP 15, 2022, View Source [SID1234638729]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Athebio will provide 3T with Athebody DARPins selected from its proprietary library against undisclosed peptide antigens presented on the cell surface by major histocompatibility complex (MHC) proteins. 3T may option the selected Athebody DARPins for further development.

"We are looking forward to working with the highly talented team at 3T Biosciences. We believe that Athebody DARPins have ideal properties to optimally recognize pMHC targets with very high specificity, which is crucial to be successful in this space," said Patrik Forrer, CEO and Chairman at Athebio, and one of the inventors of the DARPin technology.

"Combined with other key characteristics like their superior manufacturability and their ease of constructing multi-specific binders, Athebody DARPins will prove a great asset for various molecular formats, including the field of T-cell engagement. We are looking forward to exploring this huge potential together with 3T Biosciences."